¼¼°èÀÇ Æó¼¶À¯Áõ Ä¡·á ½ÃÀå
Pulmonary Fibrosis Treatment
»óǰÄÚµå : 1793756
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 376 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Æó¼¶À¯Áõ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 42¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 32¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Æó¼¶À¯Áõ Ä¡·á ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£¿¡ CAGR 5.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 42¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ´Üµ¶¿ä¹ýÀº CAGR 5.6%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 27¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º´¿ë¿ä¹ý ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8¾ï 5,970¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Æó¼¶À¯Áõ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 8¾ï 5,970¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 8¾ï 9,480¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 9.1%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.0%¿Í 3.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Æó¼¶À¯Áõ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Æó¼¶À¯ÁõÀÌ È£Èí±â Ä¡·áÁ¦ÀÇ ÃÖ¿ì¼± Ÿ°ÙÀ¸·Î ¶°¿À¸£°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

Æó¼¶À¯Áõ, ƯÈ÷ Ư¹ß¼º Æó¼¶À¯Áõ(IPF)Àº ÁøÇ༺, ºñ°¡¿ª¼º, Àå±âÀûÀÎ ¿¹Èİ¡ ÁÁÁö ¾Ê¾Æ Á¦¾àȸ»ç ¹× ÀÇ·á°èÀÇ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ ÁúȯÀº ÆóÁ¶Á÷ÀÇ ÈäÅͰ¡ Ư¡À̸ç, Æó ±â´É, ¿îµ¿ ´É·Â, »ýÁ¸À²ÀÌ ²ÙÁØÈ÷ °¨¼ÒÇÏ´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. IPFÀÇ Æò±Õ »ýÁ¸±â°£Àº Áø´Ü ÈÄ 3-5³âÀ̸ç, Ä¡·á¹ýÀÇ Çõ½ÅÀº ¿ª»çÀûÀ¸·Î Á¦ÇÑÀûÀ̾ú½À´Ï´Ù. ±×·¯³ª Áø´Ü ÀνÄÀÇ Çâ»ó, ÷´Ü ¿µ»ó Áø´Ü, ¹ÙÀÌ¿À¸¶Ä¿¸¦ ÀÌ¿ëÇÑ °èÃþÈ­ µîÀ¸·Î Á¶±â °³ÀÔÀÌ °¡´ÉÇØÁ® Ä¡·á °¡´ÉÇÑ È¯ÀÚ±ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

IPF ¹× ±âŸ ¼¶À¯¼º °£Áú¼º ÆóÁúȯ(ILDs)Àº °í·ÉÈ­, ȯ°æ ³ëÃâ, ·ù¸¶Æ¼½º °üÀý¿° ¹× Àü½Å¼º °æÈ­Áõ°ú °°Àº µ¿¹Ý ÁúȯÀ¸·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ±× ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¶À¯È­ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ÀÌÇØµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó Æó ±â´É ÀúÇϸ¦ ´ÊÃß±â À§ÇØ Ç×¼¶À¯È­ ¿ä¹ýÀ» Áúº´ °æ°ú Ãʱ⿡ ½ÃÀÛÇØ¾ß ÇÑ´Ù´Â °ø°¨´ë°¡ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ¹Ì±¹ ÈäºÎÇÐȸ(ATS)¿Í °°Àº ´ÜüÀÇ °¡À̵å¶óÀÎÀÌ ¹ßÀüÇÏ¿© ÀÏ»óÀûÀÎ Æó ±â´É ¸ð´ÏÅ͸µ°ú Ä¡·áÁ¦¿¡ ´ëÇÑ Á¶±â Á¢±ÙÀ» ¿ËÈ£Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, Ä¡·á¹ýÀº ´ëÁõ¿ä¹ý¿¡¼­ Áúº´ º¯Çü Ä¡·á·Î ÀüȯµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå °³Ã´À» Çü¼ºÇϰí ÀÖ´Â ¾àÁ¦ Ŭ·¡½ºº°, ½Å±Ô ±âÀüº°, ȯÀÚÃþÀº?

ÇöÀç Ä¡·áÀÇ ÁÖ·ù´Â ÇǸ£Æä´Ïµ·(¿¡½ººê¸®Æ®)°ú ´ÑÅ×´Ù´Õ(¿ÀÆäºê)ÀÇ µÎ °¡Áö Ç×¼¶À¯È­Á¦ÀÔ´Ï´Ù. µÎ ¾àÁ¦´Â ¹Ì±¹, EU, ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ IPF Ä¡·áÁ¦·Î ½ÂÀεǾúÀ¸¸ç, °­Á¦ÆóȰ·®(FVC) °¨¼Ò¸¦ Áö¿¬½ÃŰ´Â È¿°ú°¡ ÀÔÁõµÇ¾ú½À´Ï´Ù. ÇǸ£Æä´Ïµ·Àº °æ±¸¿ë ÇǸ®µ·°è È­ÇÕ¹°·Î TGF-β&¸¦ ºñ·ÔÇÑ ¼¶À¯È­ »çÀÌÅäÄ«ÀÎÀ» ¾ïÁ¦ÇÏ¿© Ç׿°Áõ ÀÛ¿ë°ú Ç×¼¶À¯È­ ÀÛ¿ëÀ» ¹ßÈÖÇÕ´Ï´Ù. Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦ÀÎ ´ÑÅ×´Ù´ÕÀº PDGF, FGF, VEGF µîÀÇ °æ·Î¸¦ Ç¥ÀûÀ¸·Î »ï½À´Ï´Ù. µÎ ¾à¹° ¸ðµÎ ¼ÒÈ­±â ºÎÀÛ¿ëÀÌ ÀÖ¾î Àå±âÀûÀÎ ¼øÀÀµµ°¡ ÇÊ¿äÇÏÁö¸¸, ´ëºÎºÐÀÇ °í¼Òµæ ±¹°¡¿¡¼­´Â ¿©ÀüÈ÷ Ç¥ÁØ Ä¡·á¹ýÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

´ÑÅ×´Ù´ÕÀº IPF»Ó¸¸ ¾Æ´Ï¶ó ÁøÇ༺ ¼¶À¯¼º ILD, Àü½Å¼º °æÈ­Áõ °ü·Ã ILD±îÁö ÀûÀÀÁõÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¿©·¯ ¼¶À¯È­ º´Å¿¡ ´ëÇÑ Ç×¼¶À¯È­ ¾à¹°ÀÇ Æ÷Áö¼Å´×À» º¯°æÇÏ´Â º¸´Ù ±¤¹üÀ§ÇÑ Ãß¼¼¸¦ ¹Ý¿µÇÕ´Ï´Ù. ÇöÀç ÀÓ»ó½ÃÇè¿¡¼­´Â Ç×¼¶À¯È­Á¦ ¹× ¸é¿ªÁ¶ÀýÁ¦, Ç×¼¼Æ÷ÀÎÀÚ ¿ä¹ý, Ç׳ëÈ­Á¦ µîÀÇ º´¿ë¿ä¹ýÀÌ ½ÃÇèµÇ°í ÀÖ½À´Ï´Ù. PLN-74809(Pliant TherapeuticsÀÇ µà¾ó ÀÎÅױ׸° ¾ïÁ¦Á¦)¿Í PRM-151(ziltivekimab)°ú °°Àº Ç¥Àû ºÐÀÚ´Â ¼¶À¯¾Æ¼¼Æ÷ÀÇ È°¼ºÈ­¿Í ECM ¸®¸ðµ¨¸µÀ» ¾ïÁ¦ÇÏ´Â ¸ñÀûÀ¸·Î °³¹ß ÁßÀÔ´Ï´Ù. ¼Ò¾Æ ¼¶À¯¼º ÆóÁúȯ, Äڷγª ÀÌÈÄ Æó¼¶À¯Áõ°ú °°Àº Èñ±Í ȯÀÚ ÄÚȣƮµµ ÆÄÀÌÇÁ¶óÀÎ ´Ù°¢È­ Àü·«¿¡¼­ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù.

Áø´Ü, µðÁöÅÐ µµ±¸, ÀÓ»ó °¡À̵å¶óÀÎÀº Ä¡·áÀÇ º¸±Þ°ú ÃÖÀûÈ­¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

°íÇØ»óµµ ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(HRCT), Æó »ý°Ë ±â¼ú, µðÁöÅРûÁø µµ±¸ÀÇ °³¼±À¸·Î Áø´ÜÀÇ Á¤È®µµ°¡ Çâ»óµÇ°í, ¼¶À¯ÁõÀÇ ÇÏÀ§ À¯Çü¿¡ ´ëÇÑ °èÃþÈ­°¡ °¡´ÉÇØÁ³½À´Ï´Ù. °ú¹Î¼º Æó·ÅÀ̳ª ºñƯÀÌÀû °£Áú¼º Æó·Å°ú °°Àº ´Ù¸¥ ILD¿Í IPF¸¦ ±¸º°ÇÏ´Â ´É·ÂÀº Ä¡·áÀÇ Â÷À̸¦ °í·ÁÇÒ ¶§ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. HRCT¿¡¼­ ÀϹÝÀûÀÎ °£Áú¼º Æó·Å(UIP)°ú °°Àº ÆÐÅÏÀ» Áø´ÜÇϱâ À§ÇÑ º¸Á¶ ¼ö´ÜÀ¸·Î AI¸¦ Ȱ¿ëÇÑ À̹ÌÁö ºÐ¼® ¹× ¸Ó½Å·¯´× ÅøÀÌ µîÀåÇϰí ÀÖÀ¸¸ç, Ä¡·á Àû°Ý¼º ¹× ½ÃÇè ¸ðÁý¿¡ Á¤º¸¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿ø°ÝÀÇ·á Ç÷§Æû°ú µðÁöÅÐ ÈíÀÔ ¼øÀÀµµ µµ±¸´Â ƯÈ÷ ¿ø°ÝÁö³ª ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ªÀÇ È¯ÀÚµéÀ» ´ë»óÀ¸·Î ¸¸¼ºÁúȯ °ü¸®¸¦ µ½°í ÀÖ½À´Ï´Ù. ȯÀÚ º¸°í °á°ú ÃøÁ¤(PROM)°ú ¸ð¹ÙÀÏ Ã´ÃßÃø¸¸¼úÀº Á¾´ÜÀû ¸ð´ÏÅ͸µÀÇ Æ²¿¡ Á¡Á¡ ´õ ÅëÇյǰí ÀÖÀ¸¸ç, ÀÓ»óÀǰ¡ ȯÀÚÀÇ ±â´É ¹× ÁøÇà ¼Óµµ¿¡ µû¶ó Ä¡·á ¿ä¹ýÀ» Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ATS, ERS, NICE µîÀÇ ´ÜüÀÇ °¡À̵å¶óÀο¡¼­´Â ÇöÀç ´ÙÇÐÁ¦Àû ³íÀÇ(MDD)¿Í 3-6°³¿ù¸¶´Ù Á¤±âÀûÀÎ ±â´ÉÆò°¡¸¦ °­Á¶Çϰí ÀÖÀ¸¸ç, À̸¦ ÅëÇØ Ä¡·á Á¶Á¤°ú Àû½Ã ¿¡½ºÄ÷¹À̼ÇÀ» ¿ëÀÌÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

¼¼°è Æó¼¶À¯Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼¼°è Æó¼¶À¯Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº Áúº´ À¯º´·ü Áõ°¡, Ç×¼¶À¯È­ Ä¡·áÀÇ ÀûÀÀÁõ È®´ë, ¿©·¯ ¼¶À¯¼º ILD ¾ÆÇü¿¡ °ÉÄ£ źźÇÑ ÆÄÀÌÇÁ¶óÀÎ Çõ½Å¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹, EU, ÀϺ»ÀÇ ³ôÀº ¹ÌÃæÁ· ÀÓ»ó ¼ö¿ä, Èñ±ÍÁúȯ Ä¡·áÁ¦(Èñ±ÍÀǾàǰ) ƯÇý, ¾à»ç¹ý ±ÔÁ¦ ½Å¼ÓÈ­ µîÀ¸·Î Á¦¾à±â¾÷ÀÇ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÌ È£Èí±â ³»°ú ³×Æ®¿öÅ©¸¦ ÅëÇØ Á¶±â ¹ß°ß¿¡ Àͼ÷ÇØÁö¸é Áø´Ü ¹× Ä¡·á ´ë»óÀÌ Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, »ý¸í°øÇбâ¾÷°ú ´ëÇü Á¦¾à»ç¿ÍÀÇ Àü·«Àû Á¦ÈÞ, ¶óÀ̼±½Ì °è¾à, Àμö¸¦ ÅëÇØ ÀÓ»ó °³¹ßÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ½ÇÁ¦ ÀÓ»óÀû ±Ù°Å°¡ ½ÃÀå ÁøÀÔ ¹× °¡°Ý Àü·«¿¡ ¹Ý¿µµÇ´Â °æÇâÀÌ °­È­µÇ°í ÀÖÀ¸¸ç, ½ÅÈï ½ÃÀå¿¡¼­µµ °í°¡ÀÇ Ç×¼¶À¯È­Á¦°¡ ´õ ±¤¹üÀ§ÇÏ°Ô ±Þ¿©È­µÇ´Â Ãß¼¼ÀÔ´Ï´Ù. Áö¿ªÀûÀ¸·Î´Â ºÏ¹Ì¿Í ¼­À¯·´ÀÌ Áø´Ü ¹× Ä¡·á¹ý º¸±Þ¿¡ ÀÖ¾î ¼±µÎ¸¦ ´Þ¸®°í ÀÖÁö¸¸, ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ÀÎÁöµµ Çâ»ó°ú »óȯ Á¤Ã¥ÀÇ ÁøÈ­·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷À¸·Î´Â ·Î½´, º£¸µ°ÅÀΰÖÇÏÀÓ, ÆÄÀ̺ê·ÎÁ¨, ÇÁ¶óÀÌ¾ðÆ® Å×¶óǻƽ½º, °¥¶óÆÄ°í½º NV, º§·¹·ÎÆù Å×¶óǻƽ½º, À¯³ªÀÌÆ¼µå Å×¶óǻƽ½º µîÀÌ ÀÖ½À´Ï´Ù. Â÷¼¼´ë ¼¶À¯Áõ Ä¡·áÁ¦ ¹× µ¿¹ÝÁø´Ü ¾à¹°ÀÇ µîÀåÀÌ ¿¹»óµÊ¿¡ µû¶ó, ÀÌ ½ÃÀåÀº Á¤¹Ð Ä¡·á, Á¶±â Ä¡·á ½ÃÀÛ, ÀüÀÎÀû ȯÀÚ °ü¸® ¸ðµ¨À» Áß½ÉÀ¸·Î Àå±âÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

ºÎ¹®

Ä¡·á À¯Çü(´Üµ¶¿ä¹ý, º´¿ë¿ä¹ý, ´ëÁõ¿ä¹ý), ÀûÀÀÁõ(Ư¹ß¼º Æó¼¶À¯Áõ, °¡Á·¼º PF, ±âŸ ÀûÀÀÁõ), À¯Åë ä³Î(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, Åë½ÅÆÇ¸Å ¾à±¹ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pulmonary Fibrosis Treatment Market to Reach US$4.2 Billion by 2030

The global market for Pulmonary Fibrosis Treatment estimated at US$3.2 Billion in the year 2024, is expected to reach US$4.2 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Monotherapy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Combination Therapy segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$859.7 Million While China is Forecast to Grow at 9.1% CAGR

The Pulmonary Fibrosis Treatment market in the U.S. is estimated at US$859.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$894.8 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Pulmonary Fibrosis Treatment Market - Key Trends & Drivers Summarized

Why Is Pulmonary Fibrosis Emerging as a High-Priority Target in Respiratory Therapeutics?

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), has drawn increasing focus from pharmaceutical developers and healthcare systems due to its progressive, irreversible nature and poor long-term prognosis. The disease is characterized by scarring of lung tissues, leading to a steady decline in lung function, exercise capacity, and ultimately survival. IPF has a median survival time of three to five years post-diagnosis, and therapeutic innovation has been historically limited. However, rising diagnostic awareness, advanced imaging modalities, and biomarker-led stratification are facilitating earlier intervention and expanding the treatment-eligible patient pool.

The global burden of IPF and other fibrotic interstitial lung diseases (ILDs) is increasing due to aging populations, environmental exposures, and comorbid conditions such as rheumatoid arthritis and systemic sclerosis. As understanding of fibrotic mechanisms improves, there is a growing consensus that antifibrotic therapies should be initiated earlier in the disease course to decelerate lung function loss. This has led to evolving guidelines by organizations such as the American Thoracic Society (ATS), advocating for routine pulmonary function monitoring and earlier access to therapeutic agents. As a result, the therapeutic landscape is transitioning from symptom management to disease-modifying interventions.

Which Drug Classes, Novel Mechanisms, and Patient Segments Are Shaping Market Development?

The current treatment landscape is dominated by two antifibrotic agents: pirfenidone (Esbriet) and nintedanib (Ofev). Both drugs received approval in the U.S., EU, and Asia-Pacific for IPF management and have demonstrated efficacy in slowing forced vital capacity (FVC) decline. Pirfenidone, an oral pyridone compound, exerts anti-inflammatory and antifibrotic effects by inhibiting TGF-β and other fibrogenic cytokines. Nintedanib, a tyrosine kinase inhibitor, targets pathways including PDGF, FGF, and VEGF. Both agents are associated with gastrointestinal side effects and require long-term compliance, yet remain the standard of care in most high-income countries.

Beyond IPF, nintedanib has gained expanded indication for progressive fibrosing ILDs and systemic sclerosis-associated ILD. This reflects a broader trend in repositioning antifibrotics for multiple fibrotic pathologies. Clinical trials are now testing combination regimens, including the pairing of antifibrotics with immunomodulators, anti-cytokine therapies, and senolytic agents. Targeted molecules such as PLN-74809 (a dual integrin inhibitor by Pliant Therapeutics) and PRM-151 (ziltivekimab) are under development with the aim to interrupt fibroblast activation and ECM remodeling. Rare patient cohorts, such as pediatric fibrotic lung disease and post-COVID pulmonary fibrosis, are also gaining attention in pipeline diversification strategies.

How Are Diagnostics, Digital Tools, and Clinical Guidelines Impacting Treatment Uptake and Optimization?

Improved high-resolution computed tomography (HRCT), lung biopsy techniques, and digital auscultation tools are enhancing diagnostic accuracy and enabling stratification of fibrosis subtypes. The ability to distinguish IPF from other ILDs-such as hypersensitivity pneumonitis and nonspecific interstitial pneumonia-is critical, given treatment differences. AI-powered imaging analysis and machine learning tools are emerging as aids in diagnosing patterns such as usual interstitial pneumonia (UIP) on HRCT, which can inform treatment eligibility and trial recruitment.

Telehealth platforms and digital inhaler adherence tools are supporting chronic disease management, especially for patients in remote or underserved areas. Patient-reported outcome measures (PROMs) and mobile spirometry are increasingly integrated into longitudinal monitoring frameworks, allowing clinicians to tailor treatment regimens based on patient functionality and progression speed. Guidelines from organizations such as ATS, ERS, and NICE now emphasize multidisciplinary discussions (MDDs) and routine functional assessment every 3-6 months, facilitating treatment adjustment and timely escalation.

What Factors Are Driving the Growth of the Global Pulmonary Fibrosis Treatment Market?

The growth in the global pulmonary fibrosis treatment market is driven by rising disease prevalence, expanding indications for antifibrotic therapies, and robust pipeline innovation across multiple fibrotic ILD subtypes. Pharmaceutical interest is further fueled by high unmet clinical needs, orphan drug incentives, and accelerated regulatory pathways in the U.S., EU, and Japan. As healthcare systems become more adept at early detection through pulmonology networks, the diagnosed and treated population base is expected to expand significantly.

Furthermore, strategic collaborations, licensing deals, and acquisitions between biotechs and large pharma players are facilitating faster clinical development. Real-world evidence is increasingly being incorporated into market access and pricing strategies, enabling broader reimbursement of high-cost antifibrotics in emerging markets. Geographically, North America and Western Europe continue to lead in terms of diagnosis and therapy adoption, but Asia-Pacific markets are seeing rapid growth due to increasing awareness and evolving reimbursement policies.

Major market participants include Roche, Boehringer Ingelheim, FibroGen, Pliant Therapeutics, Galapagos NV, Bellerophon Therapeutics, and United Therapeutics. With the anticipated arrival of next-generation fibrosis inhibitors and companion diagnostics, the market is poised for long-term growth centered on precision therapy, earlier treatment initiation, and holistic patient care models.

SCOPE OF STUDY:

The report analyzes the Pulmonary Fibrosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Monotherapy, Combination Therapy, Symptomatic Treatment); Indication (Idiopathic Pulmonary Fibrosis, Familial PF, Other Indications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacy Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â